Atlantic Health Strategies

DOJ Self-Disclosure for Behavioral Health Operators: A Decision Framework for Billing Errors, EKRA Risk, and Credentialing Gaps

Table of Contents

Ready to See Results?

From strategy through execution, Atlantic Health Strategies integrates compliance, operations, and growth into durable, measurable results. Let’s put our expertise to work for your organization.

The disclosure decision, stated plainly

Behavioral health operators who uncover credible evidence of federal healthcare fraud should retain outside counsel the same week, run a scoped internal investigation, and self-disclose to the appropriate DOJ component before the government learns about the conduct from any other source. Operators who disclose on that timeline qualify for the DOJ Corporate Enforcement Policy’s declination pathway, earn cooperation credit, and resolve matters at a fraction of the financial exposure they would face if a relator reached DOJ first. Self-disclosure is not immunity. Operators have to fully cooperate, remediate on a documented timeline, and disgorge ill-gotten gains, and prosecutors apply the eligibility criteria strictly.

The stakes are not theoretical. DOJ recovered over $2.9 billion in False Claims Act settlements and judgments in fiscal year 2024, and nearly $1.7 billion of that total came from the healthcare industry. That same year saw the highest number of qui tam actions filed in a single year, with 979 lawsuits, which means the odds that a disgruntled former clinician, biller, or utilization reviewer gets to the government before the operator does are higher than they have ever been.

What the March 2026 DOJ Corporate Enforcement Policy actually requires

Pull quote: Voluntary self-disclosure plus full cooperation plus timely remediation equals presumptive declination.

On March 10, 2026, the Department of Justice released its first-ever department-wide Corporate Enforcement and Voluntary Self-Disclosure Policy (CEP), replacing a patchwork of component-specific programs. The new policy supersedes the existing patchwork of component-specific and district-specific voluntary self-disclosure policies, replacing them with a single framework that applies across all DOJ criminal components (with the exception of antitrust matters). For a behavioral health operator, that means the same baseline framework applies whether the matter is handled by the Criminal Division, a U.S. Attorney’s Office, or the newly formed National Fraud Enforcement Division.

The core architecture is simple to describe and hard to execute. Voluntary self-disclosure plus full cooperation plus timely remediation equals a presumptive declination. The CEP maintains the May 2025 Criminal Division’s policy move from a “presumption” of declination to a commitment that DOJ “will” decline prosecution when the criteria are met, absent aggravating circumstances. There are two timing traps operators keep walking into. First, the voluntary disclosure must occur prior to an imminent threat of disclosure or government investigation. Second, if a whistleblower reaches DOJ first, there is still a narrow runway: under the policy’s Corporate Whistleblower Awards Pilot Program exception, a company can still earn a declination even if a whistleblower reports to DOJ first, provided the company self-discloses within 120 days of receiving the whistleblower’s internal report and otherwise meets the requirements for voluntary self-disclosure.

Operators should also understand what happens when the facts are messy. A “near miss” situation occurs where a company has self-reported, fully cooperated, and undertaken timely and appropriate remediation but is ineligible for a declination because its self-report did not meet the CEP’s definition of a “voluntary” self-disclosure or aggravating factors were present. In those cases operators still earn meaningful credit, but the outcome shifts from declination to a non-prosecution agreement, deferred prosecution agreement, or reduced penalty.

DOJ versus HHS-OIG SDP versus CMS SRDP: picking the right door

Operators and their counsel are usually choosing among three disclosure venues, and the choice drives the economics. The HHS-OIG Health Care Fraud Self-Disclosure Protocol (SDP) is the right venue for most civil overpayment, false billing, and Anti-Kickback Statute exposure that does not rise to a clear criminal matter. OIG reported that between the SDP’s launch in 1998 and 2020, it resolved more than 2,200 self-disclosures, resulting in recoveries to federal health care programs of more than $870 million.

The financial case for SDP is concrete. OIG’s general practice when entering settlements of SDP matters is to require a minimum multiplier of 1.5 times the single damages, although the OIG determines in each case whether it believes that a higher multiplier is warranted. Compare that to False Claims Act exposure of up to treble damages plus per-claim penalties when the government or a relator finds you first. The OIG doubled the minimum settlement amount for disclosed potential violations of the Anti-Kickback Statute from $50,000 to $100,000 and doubled the minimum settlement for all other matters from $10,000 to $20,000 in the November 2021 update. For Stark Law exposure, operators generally use the CMS Self-Referral Disclosure Protocol instead.

The difference between venues is not just the math. As McDermott Will & Emery notes in its DOJ-vs-OIG analysis, the DOJ policy offers declination to prosecute, while the OIG protocol offers a lower damages multiplier, a presumption against integrity agreement obligations, a streamlined process, and suspended overpayment reporting requirements. Last month, DOJ and HHS-OIG took a step to reduce the forum-shopping headache. The U.S. Department of Justice and Department of Health and Human Services have announced a coordinated policy allowing companies to make a single voluntary disclosure of potential criminal health care fraud to receive benefits under both agencies’ programs. Even so, counsel should make the choice of venue as a strategic call, not an administrative one.

What behavioral health operators actually need to do before picking up the phone

The common trigger scenarios in behavioral health are predictable. PHP billed on weeks that did not hit the required weekly hour minimum. IOP claims submitted before attendance was finalized and reconciled. Marketing arrangements, lab referral deals, or sober-home relationships that look a lot like EKRA violations under 18 U.S.C. § 220. Credentialing files where a supervising clinician’s license lapsed and nobody flagged it before claims kept flowing. A newly discovered authorization mismatch where billed services do not match the ASAM level of care actually delivered.

Before any disclosure letter leaves the building, the operator and counsel should lock down five things:

  • Scope the conduct accurately. Operators should preserve charts, EMR audit trails, UR notes, authorization logs, attendance records, and billing exports under a legal hold the moment a credible issue surfaces.
  • Quantify the exposure. Damages to federal programs (Medicare, Medicaid, TRICARE) drive both the SDP minimums and any FCA calculation. Guessing is not a substitute for a real claims analysis.
  • Fix the system that failed. Operators have to document and implement a corrective action plan, not just promise one. DOJ and OIG both weigh timely remediation heavily.
  • Preserve privilege. Counsel should direct internal investigation work from day one. Operator-side notes, Slack messages, and informal emails routinely become exhibits.
  • Decide on individual accountability. The DOJ’s long-standing posture is that prosecutors condition cooperation credit in part on the company providing facts about the individuals involved in the misconduct.

One quotation worth sitting with, from the Cooley investigations team’s analysis of the March 2026 CEP: “Because of the exacting requirements for a company to be eligible for a Tier 1 full declination, companies should work with counsel to carefully determine whether and how to present a self-report to the DOJ.” That is especially true for PE-backed platforms, where a founder’s instinct to handle a problem internally and move on can blow up the deal at the next sponsor’s quality-of-earnings review.

Pull quote: Guessing at exposure is not a substitute for a real claims analysis.

Frequently asked questions

Does self-disclosing to HHS-OIG also satisfy DOJ reporting obligations?
Not automatically, though the gap narrowed in October 2026. DOJ and HHS announced a coordinated policy allowing companies to make a single voluntary disclosure of potential criminal health care fraud to receive benefits under both agencies’ programs. For civil-only matters, SDP alone generally suffices, but OIG routinely coordinates with DOJ and DOJ can elevate a matter it finds significant. Counsel should map the disclosure strategy to both tracks before submission.

What triggers the 60-day overpayment clock after discovering a billing error?
Under ACA Section 6402 and the subsequent CMS rule, the 60-day clock to report and return an identified overpayment starts when the operator has, through reasonable diligence, identified and quantified the overpayment. The clock does not start on the first whiff of a problem; it starts once a reasonable inquiry has confirmed the overpayment and its amount. Running the inquiry promptly is itself part of the diligence standard. One benefit of entering SDP is that OIG suspends the overpayment reporting obligation during the SDP process.

Can an operator self-disclose EKRA violations tied to marketing or patient brokering arrangements?
Yes, and operators should take this seriously. The Eliminating Kickbacks in Recovery Act (18 U.S.C. § 220) is a criminal statute reaching clinical treatment facilities, laboratories, and recovery homes, and DOJ has brought EKRA cases against SUD providers. Operators can disclose EKRA conduct through the DOJ CEP track for criminal exposure and, where it overlaps with AKS and federal program claims, through SDP for the civil overpayment and CMP exposure. The analysis is fact-specific and should be run by counsel.

How do self-disclosure outcomes differ for PE-backed platforms versus independent operators?
PE-backed platforms face a different calculus. Successor liability, representations and warranties from the acquisition, disclosure obligations to lenders, and the sponsor’s reputational exposure all enter the equation. Independent operators have fewer stakeholders but often less liquidity to fund the settlement. Companies that invest in the healthcare space should be especially attentive since there has been an uptick in claims filed, Civil Investigative Demands issued, and investigations opened against private equity sponsors of healthcare companies.

What internal investigation steps should precede a voluntary disclosure to preserve privilege and cooperation credit?
Counsel-directed scoping memo, written legal hold, interviews documented under privilege, forensic preservation of EMR and billing data, a damages model tied to actual federal program payments, and a written corrective action plan tied to the root cause. Operators who skip any of these steps routinely find themselves negotiating from a weaker position because they cannot credibly show DOJ or OIG what happened, what they fixed, and how.

Request a Free Consultation

Scroll to Top